Our aim is to revolutionize drug screening by significantly reducing the time required through our innovative microfluidic-microelectrode array (MEA) brain-on-a-chip system. This advanced technology offers rapid, high-throughput capabilities while ensuring the highest level of accuracy through incorporation of biologically-relevant standards such as the blood-brain barrier.
Our brain-on-a-chip microfluidic device mimics the 3D microenvironment of the human brain, including the blood-brain barrier, to accurately predict drug responses.
We offer two product configurations: the µBrain with 8 microfluidic devices and the µBrain-MEA featuring a single microelectrode array (MEA) for real-time electrophysiological monitoring.
Our platform accelerates neurological drug development by examining clinically relevant data such as vessel permeability, characterizing drug effects on the brain, and decreasing experimental costs for developers.
Implementing a more physiologically relevant environment to expedite processing time and improve accuracy.
- Tailored experiments- Expert consultation- Detailed scientific points
Comparing our innovative solutions with existing products in the market.
Our novel approach offers a potentially patentable technology with a unique selling point: it leverages the use of living human blood vessels to more accurately simulate the blood-brain barrier. This innovation provides more physiologically relevant results, mimicking drug delivery into the brain with greater precision, while maintaining high cost-efficiency and customer-oriented service.
Our business model bridges innovative solutions to both biotech companies and research institutions. By fostering strong partnerships and leveraging our expertise, we aim to drive advancements in the biotech field and support groundbreaking research initiatives. Our dual approach ensures we cater to the unique needs of each sector, promoting growth and development across the industry.
